Roth Capital raised the firm’s price target on CapsoVision (CV) to $11 from $7 and keeps a Buy rating on the shares after the company announced preliminary sales for Q4 of $3.9M, the closing of a $14M private placement, consisting of about 2.87M shares sold at $4.883 per share and also provided an update regarding CapsoCam Colon and its Breakthrough Device Designation for early pancreatic cancer detection.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CV: